Zebrafish Water Tank Model: A Review of Drug Metabolism Research
Background
Understanding drug metabolism is critical for developing safe and effective therapeutics, yet traditional animal models can be costly and time-consuming. The zebrafish (Danio rerio) has emerged as a promising alternative, offering a balance of biological complexity and experimental tractability. This review comprehensively addresses the current state, future potential, and inherent challenges of utilizing zebrafish water tank models for investigating drug metabolism.
Study Design
Results
The review highlighted that zebrafish (Danio rerio) models possess significant advantages for investigating drug metabolism, primarily due to their high genetic homology with humans, estimated at approximately 70%, alongside their rapid development cycle and high fecundity. They found these models are particularly effective in assessing both phase I (e.g., oxidation, reduction via cytochrome P450 enzymes) and phase II (e.g., glucuronidation, sulfation) metabolic reactions, crucial for understanding drug fate in vivo. > The model has been successfully applied to investigate the metabolism of a diverse range of compounds, including anticancer drugs, antibiotics, and environmental toxins, demonstrating its versatility and ability to mimic mammalian metabolic pathways with over 80% concordance in some drug classes. The authors observed a robust increase in research output, with publications utilizing zebrafish for drug metabolism studies showing an average annual growth rate of 15-20% over the past decade, underscoring its increasing acceptance. Furthermore, the review detailed how zebrafish can identify key metabolic enzymes and pathways, providing insights into potential drug-drug interactions and species-specific differences, with over 100 human orthologs of drug-metabolizing enzymes identified in the zebrafish genome.
Why It Matters
This review underscores that zebrafish models provide a cost-effective and high-throughput alternative to traditional mammalian models for early-stage drug discovery and toxicology screening. Their ability to rapidly assess metabolic profiles can significantly accelerate the identification of drug candidates with favorable pharmacokinetic properties, potentially reducing attrition rates in preclinical development by up to 30%. Further refinement and standardization of these models could lead to their broader adoption in regulatory toxicology and personalized medicine, bridging the gap between in vitro and in vivo human studies. Future work should focus on integrating advanced analytical techniques and developing more sophisticated transgenic lines to enhance their predictive power and expand their utility in complex drug-drug interaction studies.